Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06488209 · ClinicalTrials.gov registry record · Phase 1
Single and Multiple Ascending Dose Study in Healthy Participants and Participants With an Autoimmune Disease
A Phase 1 study, sponsored by Almirall, S.A..
- Completed
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
NCT06488209: Completed Phase 1 study, sponsored by Almirall, S.A..
NCT06488209 is a Phase 1 study that has completed, run by Almirall, S.A.. The registered enrollment target is 69 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (15% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06488209, a Phase 1 study, has completed, sponsored by Almirall, S.A..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
Study Summary
The main purpose of this study is to to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity of LAD191 in healthy adults and in adults with an autoimmune disease.
Interventions
- OTHER Placebo
- DRUG LAD191
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2022-07-29 |
| Est. Completion | 2025-04-03 |
| Phase | Phase 1 |
What the finished NCT06488209 record still lists
NCT06488209 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 69 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (15% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06488209 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06488209 about?
NCT06488209 is a clinical study titled "Single and Multiple Ascending Dose Study in Healthy Participants and Participants With an Autoimmune Disease". The main purpose of this study is to to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity of LAD191 in healthy adults and in adults with an autoimmune disease.
What is the current status of trial NCT06488209?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2022-07-29. Estimated completion is 2025-04-03.
What interventions are being tested in trial NCT06488209?
The interventions under investigation include: Placebo (OTHER), LAD191 (DRUG).
Who is sponsoring clinical trial NCT06488209?
This trial is sponsored by Almirall, S.A., which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06488209's enrollment target sits among peer trials
69 774th of 2000 higher than 1,225 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04020575 · 69 participants · Phase 1
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
- NCT04163614 · 69 participants · NA
Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients
- NCT04164641 · 69 participants · NA
Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic Gait Correction in Reducing Diabetic Foot Ulceration Or Subsequent Amputation in Patients With a History of a Diabetic Foot Ulceration
- NCT04493372 · 69 participants · NA
Deciphering Preserved Autonomic Function After Spinal Cord Injury
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI